Compare Bristol-Myers Squibb Co (BMY) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Global X Uranium ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.6 (market cap $116.30B), while Global X Uranium ETF trades at $40.91. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Global X Uranium ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| BMY | URA | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $62.37 | $61.81 |
52-Week Low | $42.60 | $36.45 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
URA (Global X Uranium ETF) trades at $40.72, down 5.24% over 24 hours amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though RSI indicators suggest potential oversold conditions. Recent news highlights uranium's strategic positioning at the intersection of AI power demand and nuclear energy revival, with the fund holding $6.29 billion in assets across 56 uranium-related companies.
The ETF's outlook balances near-term technical weakness against strong secular tailwinds from AI-driven electricity demand and nuclear policy support. Key risks include uranium price volatility and competition from pure-miner alternatives, while the current oversold technical condition may present entry opportunities for long-term investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
